21.76

2.94% -0.66

After Hours: 21.76

Structure Therapeutics Inc Adr (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc Adr stock is traded at $21.76, with a volume of 731.22K. It is down -2.94% in the last 24 hours and down -16.02% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Previous Close:

$22.42

Open:

$22.44

24h Volume:

731.22K

Relative Volume:

0.78

Market Cap:

$3.76B

Revenue:

Net Income/Loss:

$-100.44M

P/E Ratio:

-9.8018

EPS:

-2.22

Net Cash Flow:

$-105.32M

1W Performance:

-11.36%

1M Performance:

-16.02%

6M Performance:

-34.36%

1Y Performance:

-35.55%

1-Day Range:

$21.51

$22.59

1-Week Range:

$21.51

$24.98

52-Week Range:

$13.22

$62.74

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc Adr

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(628) 229-9277

Address

611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO

Employee

183

Twitter

Next Earnings Date

Latest SEC Filings

GPCR's Discussions on Twitter

Compare GPCR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GPCR Structure Therapeutics Inc Adr	21.76	1.41B	0	-100.44M	-105.32M	-2.22
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-02-25	Initiated	Citigroup	Buy
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy
Dec-04-24	Initiated	H.C. Wainwright	Buy
Sep-23-24	Initiated	Morgan Stanley	Overweight
May-21-24	Initiated	JP Morgan	Overweight
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

May 29, 2025

Structure Therapeutics Set for Jefferies and Goldman Sachs Healthcare Conference Presentations in June - Stock Titan

May 29, 2025

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - standard-journal.com

May 29, 2025

May 28, 2025

Bank of America Corp DE Sells 48,015 Shares of iShares MSCI Australia ETF (NYSEARCA:EWA) - Defense World

May 28, 2025

BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

May 28, 2025

May 26, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail

May 26, 2025

May 22, 2025

Structure Therapeutics’ SWOT analysis: oral obesity drug stock poised for growth - Investing.com

May 22, 2025

May 17, 2025

Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $78.00 - Defense World

May 17, 2025

May 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail

May 16, 2025

May 13, 2025

Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright - Defense World

May 13, 2025

May 12, 2025

FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World

May 12, 2025

May 09, 2025

Envestnet Asset Management Inc. Has $201,000 Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

May 09, 2025

Tower Research Capital LLC TRC Acquires 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - The AM Reporter

May 09, 2025

Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs - TipRanks

May 09, 2025

May 08, 2025

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights - Stock Titan

May 08, 2025

May 07, 2025

Wells Fargo & Company MN Boosts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

May 07, 2025

Analyzing Ratios: Structure Therapeutics Inc ADR (GPCR)’s Financial Story Unveiled - DWinneX

May 07, 2025

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC) - The Globe and Mail

May 07, 2025

May 06, 2025

Structure Therapeutics Inc ADR (NASDAQ: GPCR) Is Up 1.57% So Far This Year: What Will Happen Next? - Stocksregister

May 06, 2025

May 05, 2025

Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at Citigroup - Defense World

May 05, 2025

May 02, 2025